Ultrasound-guided fine-needle aspiration/biopsy-based pancreatic organoids establishment: an alternative model for...

Pancreatic ductal adenocarcinoma (PDAC), as one of the malignant cancers with the worst prognosis, is becoming the most urgent clinical problem. Due to the lack of early diagnosis and curable therapeutic methods, it is critical to exploit proper models that can capture the overall attributes of the primary tumor. Recently, organoid technology has emerged and flourished as a powerful tool to enable long-term culture of pancreatic tissues, including PDAC. As accumulating studies suggest, organoids can retain morphological, genetic, and behavioral traits, and have tremendous value in predicting the therapeutic response to conventional chemotherapy drugs or newfangled agents. Herein, this review comprehensively summarizes the tissue source including human fetal and adult pancreatic tissue to generate a pancreatic organoid as well as current organoids cultivate system. As PDAC organoids can be established from a small number of samples derived from endoscopic ultrasound-guided fine-needle aspiration/biopsy (EUS-FNA/FNB), we also review the literature to date on EUS-FNA/FNB-based organoid constitution and its implementation in inquiring tumor behavior and evaluating therapeutic responses. By enabling the alignment of basic and clinical research platforms, the application of organoids would open up new avenues for drug discovery and maximally benefit translational medicine in the near future.